Regulatory & Legal

A new animated video, voiced by a father and his daughter, offers hope and understanding to children battling a rare and life-threatening liver disease.

For the 11th straight year, OTAVA lands on CRN's prestigious MSP 500 list. We explore how its focus on security, compliance, and a human-first approach sets it apart.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

A new report on 1,800+ patients reveals a model for obesity care that preserves muscle, sustains weight loss, and may solve the GLP-1 cost crisis.

A 20-year fight to save Nova Scotia salmon from acid rain is now a certified climate technology, attracting major investment and creating a new model for conservation.

With a massive Series A, Alveus Therapeutics is advancing novel drugs aiming for more durable and higher-quality weight loss than current blockbusters.

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

Leading crypto ATM operator Bitcoin Depot now requires ID for every transaction, a move aimed at fighting fraud but raising questions about user access.

Facing SEC delays, Aptose Biosciences secures an $11.1M lifeline from its acquirer, Hanmi, highlighting financial strain as the critical deal moves forward.

Facing delisting, Hong Kong-based PTL Limited enacts a massive 1-for-80 share consolidation. But can this financial maneuver fix deeper business issues?

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

After repeated hurricane shutdowns, St. Petersburg invests $1M in innovative flood panels to keep its critical water facilities running.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

The junior miner sheds non-core assets to double down on its high-grade Mexican silver project while upgrading to a top-tier U.S. market.

Khazna's new 100MW facility in Ajman, the MENA region's first certified liquid-cooled AI data center, signals a major leap in digital infrastructure.

Shareholders approve a major private placement, injecting strategic capital from La Mancha to advance Brazil's controversial Volta Grande Gold Project.

A new partnership brings an FDA-designated breakthrough device to more patients, fueled by a key Medicare payment that could reshape the trauma market.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.